XML 29 R16.htm IDEA: XBRL DOCUMENT v2.3.0.15
Business Segments
9 Months Ended
Oct. 01, 2011
Business Segments [Abstract] 
Business Segments
10. Business Segments

The Company operates in two reportable segments: the ophthalmology segment and the aesthetics segment. In each segment the Company develops, manufactures, and markets medical devices. Our revenues arise from the sale of consoles, delivery devices, consumables and service and support activities.

Information on reportable segments for the three and nine month periods ended October 1, 2011 and October 2, 2010 is as follows:

 

     Three Months Ended October 1, 2011     Three Months Ended October 2, 2010  

(in thousands)

    Ophthalmology      Aesthetics      Total     Ophthalmology      Aesthetics      Total  

Revenues

    $ 8,258       $ 2,535       $ 10,793      $ 7,999       $ 2,819       $ 10,818   

Direct cost of revenues

      2,626         781         3,407        2,189         825         3,014   
  

 

 

     

 

 

     

 

 

    

 

 

     

 

 

     

 

 

  

Direct gross profit

    $ 5,632       $ 1,754         7,386      $ 5,810       $ 1,994         7,804   

Total unallocated indirect costs

            (7,001 )            (6,856 ) 
        

 

 

          

 

 

  

Pre-tax income

          $ 385            $ 948   
        

 

 

          

 

 

  

 

     Nine Months Ended October 1, 2011     Nine Months Ended October 2, 2010  

(in thousands)

    Ophthalmology      Aesthetics      Total     Ophthalmology      Aesthetics      Total  

Revenues

    $ 24,539       $ 8,264       $ 32,803      $ 23,271       $ 8,195       $ 31,466   

Direct cost of revenues

      7,453         2,611         10,064        6,562         2,438         9,000   
  

 

 

     

 

 

     

 

 

    

 

 

     

 

 

     

 

 

  

Direct gross profit

    $ 17,086       $ 5,653         22,739      $ 16,709       $ 5,757         22,466   

Total unallocated indirect costs

            (20,608 )            (20,092 ) 
        

 

 

          

 

 

  

Pre-tax income

          $ 2,131            $ 2,374   
        

 

 

          

 

 

  

Direct cost of revenues includes standard product cost (direct material, labor and fringe) and any warranty and unit royalty due. Indirect costs of manufacturing, research and development, sales and marketing, and general and administrative costs are not allocated to the segments.

Our revenues by reportable segment by geographic region, based on the location at which each sale originates, is summarized as follows:

 

     Three Months Ended October 1, 2011      Three Months Ended October 2, 2010  

(in thousands)

    Ophthalmology      Aesthetics      Total      Ophthalmology      Aesthetics      Total  

Domestic

    $ 4,403       $ 1,435       $ 5,838       $ 4,949       $ 1,584       $ 6,533   

International

      3,855         1,100         4,955         3,050         1,235         4,285   
  

 

 

     

 

 

     

 

 

     

 

 

     

 

 

     

 

 

  

Total revenues

    $ 8,258       $ 2,535       $ 10,793       $ 7,999       $ 2,819       $ 10,818   
  

 

 

     

 

 

     

 

 

     

 

 

     

 

 

     

 

 

  
     Nine Months Ended October 1, 2011      Nine Months Ended October 2, 2010  

(in thousands)

    Ophthalmology      Aesthetics      Total      Ophthalmology      Aesthetics      Total  

Domestic

    $ 13,368       $ 4,426       $ 17,794       $ 13,029       $ 4,866       $ 17,895   

International

      11,171         3,838         15,009         10,242         3,329         13,571   
  

 

 

     

 

 

     

 

 

     

 

 

     

 

 

     

 

 

  

Total revenues

    $ 24,539       $ 8,264       $ 32,803       $ 23,271       $ 8,195       $ 31,466   
  

 

 

     

 

 

     

 

 

     

 

 

     

 

 

     

 

 

  

No one customer accounted for more than 10% of total revenue for the three months ended October 1, 2011 and October 2, 2010, respectively.

The Company's assets and liabilities are not evaluated on a segment basis. Accordingly, no disclosure of segment assets and liabilities is provided.